New drug, TASCENSO ODT® (fingolimod), launched to meet the needs of multiple sclerosis patients in the US left without essential patient support

By |2023-02-13T10:54:43+00:00February 13th, 2023|News|
Read More

Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of TASCENSO ODT® (fingolimod)

By |2023-01-13T11:37:55+00:00January 16th, 2023|News|
Read More

Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023

By |2022-11-30T11:21:25+00:00November 1st, 2022|News|
Read More

Tony Cates joins Cycle Group Holdings Board of Directors

By |2022-11-30T11:31:47+00:00October 6th, 2021|News, Nityr|
Read More

Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)

By |2022-11-30T11:32:04+00:00September 28th, 2021|News, Nityr|
Read More

Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients

By |2022-11-30T11:32:18+00:00September 10th, 2021|News, Nityr|
Read More

Cycle Pharmaceuticals appoints Denise Moody as Chief Operating Officer

By |2021-06-28T11:44:17+01:00June 28th, 2021|Corporate, News|
Read More

Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer

By |2022-11-30T11:33:08+00:00May 25th, 2021|Corporate, News|
Read More

Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors

By |2022-11-30T11:33:22+00:00April 29th, 2021|News, Nityr|
Read More

NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand

By |2022-11-30T11:33:41+00:00March 15th, 2021|News, Nityr|
Read More
Go to Top